Dr Mark Roschewski speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting on the phase IB/2 results of a study evaluating the safety and efficacy of escalating doses of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma.
He explains that the study enrolled patients who were ineligible for CAR T therapy as they would be considered as having very limited treatment options.
Dr Roschewski reports that the escalating of doses means that anaemia is less of a problem and it causes the patient's haemoglobin to rise over time.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.